Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome

K G Au Eong, S Beatty, S J Charles

Infection with cytomegalovirus (CMV), an ubiquitous member of the herpes group of viruses, is very common among the general population (box 1).\(^1\) Serological studies indicate that previous exposure to CMV has occurred in a large proportion of adults throughout the world, and although the rates vary depending on the population studied, up to 90% of middle-aged adults may have been exposed. In most cases, CMV does not cause clinically apparent disease. CMV infection of the eye, however, is seen in immunocompromised individuals such as patients with acquired immune deficiency syndrome (AIDS), those with organ transplant on immunosuppressive drugs, and in congenitally infected newborns.\(^1\) \(^4\) CMV retinitis is more common in AIDS patients than in organ or bone marrow transplant recipients.

Epidemiology

The first cases of CMV retinitis in AIDS patients were reported in 1982.\(^3\) \(^4\) It is now recognised as the most common retinal infection in patients with AIDS (table 1).\(^5\) \(^6\) It tends to occur late in the course of the disease, and is associated with peripheral blood absolute CD4+ T-lymphocyte (CD4) counts below 50 cells/µl (box 2). Kuppermann and associates found that 30% of their patients with CD4 counts of less than 50 cells/µl had CMV retinitis.\(^7\) Although CMV retinitis may occasionally be seen in a patient with a CD4 count in excess of 200 cells/µl, this is not typical, and other causes of necrotising retinitis, including toxoplasmic retinochoroiditis, should be considered in the differential diagnosis. CMV retinitis may, on rare occasions, be the presenting sign of symptomatic human immunodeficiency virus (HIV) infection.\(^8\) \(^10\)

Clinical features

Symptoms

The symptoms of CMV retinitis depend on its initial location. Visual symptoms of peripheral lesions include floaters and loss of peripheral vision, but not all patients are symptomatic.\(^7\) More posteriorly located lesions result in paracentral or central scotomas. The visual loss in CMV retinitis is usually the result of retinal necrosis, but macular oedema secondary to retinitis near the macula may also reduce visual acuity. Other mechanisms which may be involved in loss of central or peripheral vision in this condition include retinal detachment and CMV papillitis.

Table 1

Prevalence of ocular findings in AIDS patients

<table>
<thead>
<tr>
<th>Ocular manifestation</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>'AIDS retinopathy'</td>
<td>64</td>
</tr>
<tr>
<td>Cotton wool spots</td>
<td>12</td>
</tr>
<tr>
<td>Intraretinal haemorrhages</td>
<td></td>
</tr>
<tr>
<td>Opportunistic ocular infections</td>
<td></td>
</tr>
<tr>
<td>CMV retinitis</td>
<td>28</td>
</tr>
<tr>
<td>Herpes zoster ophthalmicus</td>
<td>4</td>
</tr>
<tr>
<td>Presumed varicella-zoster retinitis</td>
<td>0.5</td>
</tr>
<tr>
<td>Presumed cryptococcal choroiditis</td>
<td>0.5</td>
</tr>
<tr>
<td>Toxoplasma gondii retinochoroiditis</td>
<td>1</td>
</tr>
<tr>
<td>Bacterial corneal ulcers</td>
<td>1</td>
</tr>
<tr>
<td>Ocular neoplasms</td>
<td></td>
</tr>
<tr>
<td>Eyelid Kaposi’s sarcoma</td>
<td>1.5</td>
</tr>
<tr>
<td>Conjunctival Kaposi’s sarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Neuro-ophthalmic lesions</td>
<td></td>
</tr>
<tr>
<td>Optic neuropathy</td>
<td>2.5</td>
</tr>
<tr>
<td>Papilloedema</td>
<td>1.5</td>
</tr>
<tr>
<td>Cranial nerve palsy or motility disturbance</td>
<td>4</td>
</tr>
</tbody>
</table>
UNTREATED CMV RETINITIS CAN RESULT IN A VARIETY OF CLINICAL APPEARANCES. INVASION OF THE RETINAL CELLS BY THE VIRUS CAUSES A FULL-THICKNESS RETINAL NECROSIS, AND THIS APPEARS AS MULTIPLE GRANULAR-APPEARING WHITE DOTS WITH VARYING AMOUNTS OF INTRARETINAL HAEMORRHAGE (FIGURE 1). IF LEFT UNTREATED, THESE LESIONS TEND TO ENLARGE AND COALESCE OVER TIME. AS THE RETINAL TISSUE LOSSES ITS CAPACITY TO SUPPORT VIRAL REPLICATION, THE RETINA AND THE UNDERLYING PIGMENT EPITHELIUM BECOME ATROPHIC, AND THE CHOROIDAL VASCULATURE IS THEREFORE MORE EASILY VISUALISED (FIGURE 2). CONSEQUENTLY, UNTREATED CMV RETINITIS TYPICALLY APPEARS AS AN ADVANCING EDGE OF ACTIVE, WHITE RETINITIS WITH VARYING AMOUNTS OF HAEMORRHAGE, WHICH EXTENDS FROM AN AREA OF CHORIORETINAL ATROPHY (FIGURE 3). ASSOCIATED FINDINGS WHICH MAY ALSO BE PRESENT INCLUDE VASCULAR ATTENUATION, PERIVASCULITIS (FIGURE 1), MILD VITRITIS AND ANTERIOR UVEITIS. RECURRENT RETINITIS DESPITE SPECIFIC ANTI-CMV TREATMENT TENDS TO BE INDOLENT. SERIAL FUNDAL PHOTOGRAPHY MAY HELP IN THE DETECTION OF SLOWLY EXTENDING AREAS OF ACTIVE RETINITIS (FIGURES 4 AND 5).

RETINAL DETACHMENT
Retinal detachment occurs in at least 20% of patients with CMV retinitis, and the risk appears to increase with the duration of infection. Although the full-thickness necrosis of CMV-infected retina is usually replaced by a thin glial sheet, a full-thickness retinal break or an area of multiple breaks may develop. Fluid from the vitreous cavity can then pass through the retinal break(s) and cause the sensory retina to separate from the retinal pigment epithelium, thus producing a rhegmatogenous retinal detachment.

The impact of treatment of CMV retinitis on the risk of retinal detachment remains a matter of debate. It has been suggested by some authors that ganciclovir therapy predisposes a patient to retinal detachment by reducing adhesive scar formation. It may also hasten the development of retinal detach-
ment by accelerating the healing phase of the infection, when retinal breaks are known to occur. However, the reports are not unanimous and one study actually found a reduced risk of retinal detachment with ganciclovir therapy.

Clinically, the retinal detachment may be localised or total, depending on many factors including the location and number of retinal breaks. Visual field defects resulting from regions of CMV retinitis, or a reduction in acuity resulting from involvement of the macula or optic nerve (figure 6) may delay the diagnosis of retinal detachment in these patients.

**Diagnosis**

The diagnosis of CMV retinitis is based on the clinical findings. Since the vast majority of AIDS patients have been infected with CMV, the presence of anti-CMV antibodies or the isolation of CMV from other body sites such as blood and urine cultures is insufficient to establish a diagnosis of CMV retinitis. As it is recommended that equivocal lesions should be monitored for progression without treatment, it is essential that physicians be familiar with the clinical features of CMV retinitis.

**Differential diagnoses**

The major disorders in the differential diagnosis of CMV retinitis include toxoplasmic retinochoroiditis, varicella-zoster virus retinopathy, herpes simplex virus retinopathy and syphilitic retinitis. It should be remembered, however, that these disorders can occur concurrently with CMV retinitis. In any case of presumed CMV retinitis with atypical features or poor response to therapy, concurrent infections should be considered.

**Natural history**

Untreated CMV retinitis usually progresses relentlessly, and ultimately results in irreversible blindness. It also tends to become a bilateral disease.

**Treatment**

With the drugs that are currently available to treat CMV retinitis, it is now rare for AIDS patients to die without any vision as a result of this retinal infection. The drugs currently available for treatment of CMV retinitis include ganciclovir, foscarnet and cidofovir, all of which are virustatic (boxes 3–5). They may be given systemically or locally.

**Systemic treatment**

Patients are given an initial ‘induction’ course of therapy for 14 days, designed to inactivate the CMV and prevent further enlargement of retinal lesions. Induction therapy is followed by ‘maintenance’ therapy, usually for life, to prevent disease reactivation (box 6). As the drugs are given intravenously, long-term maintenance therapy is problematic in these immunocompromised patients because of the risk of life-threatening sepsis. Furthermore, the presence of an
indwelling catheter and the time required to infuse these medications reduce the patient’s quality of life. Although oral ganciclovir obviates some of the problems associated with intravenous therapy, it has poor bioavailability and is given as maintenance therapy only. It is also less efficacious than intravenous ganciclovir.

On cessation of therapy, the average time to progression of retinitis is 2–3 weeks. In a recent randomised clinical trial, the median time to progression of disease was 47 days for patients treated with ganciclovir and 53 days for patients treated with foscarnet. Patients not on highly active anti-retroviral therapy (HAART), the disease will reactivate and progress in nearly all patients with the current anti-CMV treatment regimens, if they survive long enough. This may be due to a combination of factors including development of resistant CMV strains, a deteriorating immune status of the patients or inadequate drug dosing. However, in most cases, the first reactivation of CMV retinitis can be brought under control by administering induction-level doses of the same drug that is being used for maintenance.

Acyclovir and zidovudine (azidothymidine) in general are not effective in treating established CMV retinitis, although a few cases of CMV retinitis have been reported to resolve on zidovudine therapy, possibly as a result of temporarily improved immunocompetence.

**Local (intravitreal) therapy**

Direct injection of ganciclovir into the vitreous cavity has been used as an alternative to systemic treatment. It has the advantage of achieving therapeutic levels by circumventing the inefficiency of ganciclovir in crossing the blood–retina barrier. Moreover, the systemic exposure to ganciclovir following clearance from the eye is extremely small, avoiding associated adverse systemic effects. It is particularly suitable in patients who cannot take intravenous ganciclovir due to myelosuppression and in patients who are receiving zidovudine, which may preclude the use of intravenous ganciclovir due to the added myelosuppressive effect. In those cases that fail to respond in spite of aggressive systemic treatment, adjunctive intravitreal treatment should also be considered. Intravitreal foscarnet and intravitreal cidofovir have also been used with success in controlling CMV retinitis (box 7).

The fact that local therapy does not treat the fellow eye or non-ocular disease has been viewed as a major disadvantage. All patients with untreated CMV retinitis have evidence of non-ocular tissue-invasive CMV infections at autopsy, although not all of these infections will cause clinically apparent disease. A number of potential complications are associated with intravitreal injections. These include infectious endophthalmitis, an increased rate of retinal detachment, increased intra-ocular pressure at the time of injection, vitreous haemorrhage and retinal toxicity. Intravitreal cidofovir is also associated with iritis and hypotony.

A sustained-release ganciclovir implant has been used for intravitreal implantation with the goal of achieving a longer therapeutic effect and better control of CMV retinitis. The cumulative data indicate that the ganciclovir implant lengthens the period of disease-free time 2–4-fold compared to conventional intravenous therapy.

**TREATMENT OF RETINAL DETACHMENT**

The decision to repair any retinal detachment is determined by a careful analysis of the potential risks and complications of the operation contrasted with the likelihood of achieving a significant visual benefit. In a patient with AIDS and CMV-related retinal detachment, the determination of benefit is not usually clear-cut and the decision to operate requires special consideration of such factors as the overall clinical status and life expectancy of the patient, the status of the fellow eye, and the wishes of the patient. As a result of improved survival with better anti-retroviral treatment, there is a trend in recent years for ophthalmologists to be more aggressive in treating CMV-related retinal detachment, even if only one eye is affected. The treatment goal has gradually evolved from keeping one eye seeing until the patient passes away (previously after 3–4 months) to preserving good vision in both eyes indefinitely.

The modalities of treatment of retinal detachment include laser photocoagulation to wall off the detachment or retinal breaks and scleral buckling. However, most cases require treatment by pars plana vitrectomy combined with intravitreal gas or, more usually, silicone oil injection.

**Changing pattern of CMV retinitis**

In the past few years, a dramatic improvement in the prognosis for HIV-infected patients has been achieved with the strategy involving a combination of
anti-retroviral drugs to bring about a profound and durable suppression of viral replication.29 HAART regimens consisting of an HIV protease inhibitor combined with one or two dideoxynucleoside agents (reverse transcriptase inhibitors) dramatically increase absolute CD4 counts, reduce HIV viral load and improve survival, even in patients with very low CD4 counts.30

The incidence of CMV retinitis has declined dramatically among patients maintained on HAART. Prior to the introduction of HAART, the natural history of untreated CMV retinitis was relentless progression of full thickness retinal necrosis leading to blindness. It is now becoming clear that some patients with CMV retinitis who respond to HAART in terms of elevated CD4 count and reduced HIV viral load undergo no reactivation of their retinitis despite having no specific anti-CMV therapy.29 30 However, the factors underlying this improved immunity have not entirely abated. Most cases of HAART-induced spontaneous and sustained resolution of CMV retinitis had elevated CD4 counts. However, sustained resolution of CMV retinitis in a patient with a persistently low CD4 count has been reported.23 In some patients with healed CMV retinitis and sustained HAART-induced CD4 count elevation, close ophthalmologic observation and CD4 count monitoring may be substituted for anti-CMV therapy.

One of the features that has characterised CMV retinitis in patients with AIDS is a scarcity of inflammation in the anterior chamber and vitreous humour.31 Indeed, the presence of marked vitreous inflammation can help to differentiate CMV retinitis from other causes of retinitis in patients with AIDS, such as toxoplasmic retinochoroiditis. During treatment with HAART, a transient vitreous inflammatory reaction in patients with AIDS and CMV retinitis has been reported.32 This inflammation reflects an improved immune response against CMV, and may be associated with cystoid macular oedema and epiretinal membrane formation. This new syndrome has been named immune recovery vitritis. It responds to either systemic or repository corticosteroid therapy, without reactivation of the CMV retinitis.33

Conclusion

As anti-retroviral treatments improve, we are witnessing a change in the pattern of CMV retinitis in HIV disease.34 Although the incidence of CMV retinitis has declined with the introduction of HAART, CMV retinitis remains a threat to the vision in these patients. Physicians should therefore know when to conduct ophthalmic screening for patients with HIV disease (table 2) and be familiar with the clinical features of CMV retinitis and its recurrence.

---

Table 2  Ophthalmic screening of HIV patients

<table>
<thead>
<tr>
<th>CD4 count (cells/µl)</th>
<th>Screening interval (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤50</td>
<td>2–3 months</td>
</tr>
<tr>
<td>51–250</td>
<td>3–4 months</td>
</tr>
<tr>
<td>250–500</td>
<td>5–6 months</td>
</tr>
</tbody>
</table>

---


---

West Sussex History of Medicine Society

On Saturday mornings 9, 16, 23 October and 13, 27 November 1999 there will be a History of Medicine Course held at the Medical Education Centre, St Richard's Hospital, Chichester, from 10.00 h to midday. The course is constructed as an introduction to the History of Medicine Diploma of The Society of Apothecaries, and will include historical method, sources, local medical history, Art in medical history, and the use of primary source material. Speakers are nationally recognised experts.

The course is open to all medical practitioners, students and those interested in healthcare, but numbers are limited. The fee is £35.00 for the course or £7.50 per session and further information may be obtained from Rebecca Quick at Chichester Medical Education Centre, St Richard’s Hospital, Chichester, PO19 4SE, or tel 01243 831509.

---

West Sussex History of Medicine Society

On Saturday mornings 9, 16, 23 October and 13, 27 November 1999 there will be a History of Medicine Course held at the Medical Education Centre, St Richard's Hospital, Chichester, from 10.00 h to midday. The course is constructed as an introduction to the History of Medicine Diploma of The Society of Apothecaries, and will include historical method, sources, local medical history, Art in medical history, and the use of primary source material. Speakers are nationally recognised experts.

The course is open to all medical practitioners, students and those interested in healthcare, but numbers are limited. The fee is £35.00 for the course or £7.50 per session and further information may be obtained from Rebecca Quick at Chichester Medical Education Centre, St Richard’s Hospital, Chichester, PO19 4SE, or tel 01243 831509.